Protonix, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., is a proton pump inhibitor (PPI) medication used for the short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger-Ellison Syndrome. It is available in delayed-release tablets and oral suspension forms, with recommended dosages varying for adults and children. Protonix is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles, as well as in patients receiving rilpivirine-containing products. While Protonix is generally well-tolerated, there are several warnings and precautions associated with its use, including the possibility of gastric malignancy, acute tubulointerstitial nephritis, Clostridium difficile-associated diarrhea, bone fractures, severe cutaneous adverse reactions, cutaneous and systemic lupus erythematosus, cyanocobalamin vitamin B-12 deficiency, hypomagnesemia and mineral metabolism disorders, and the risk of fundic gland polyps. Adverse reactions may include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, arthralgia, upper respiratory tract infection, fever, rash, and abdominal pain. Protonix may interact with other medications, and caution should be exercised in specific populations such as pregnant women and pediatric patients. Generated from the website